0
ARTICLE |

The Role of Immunotherapy in Acute Myelogenous Leukemia

Kenneth A. Foon, MD; Richard V. Smalley, MD; Charles W. Riggs; Robert Peter Gale, MD, PhD
Arch Intern Med. 1983;143(9):1726-1731. doi:10.1001/archinte.1983.00350090104017.
Text Size: A A A
Published online

• The use of immunotherapy for acute myelogenous leukemia (AML) is controversial. Twenty-four trials have been reported in which 1,491 patients with AML received various forms of immunotherapy, including BCG, methanol extract residue (MER) of BCG, or Corynebacterium parvum. Some patients were immunized with allogeneic or autologous leukemia blast cells. In only four of the 24 trials was a significant prolongation of remission reported. Pooled data from all 24 studies were analyzed further. No statistically significant difference in duration of remission between patients who received maintenance chemotherapy alone and those who received maintenance chemotherapy plus immunotherapy was found. A significant survival advantage for those patients who received BCG and chemotherapy for maintenance therapy was detected. A beneficial biologic effect for the patients treated with BCG is suggested but this was not a disease-free survival advantage, and had no impact on cure of patients with AML. Immunotherapy, as currently conceived, seems to have no substantial benefit for patients with AML receiving optimal chemotherapy.

(Arch Intern Med 1983;143:1726-1731)

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();